Mitochondrial Releasates

For both a conventional CDx as well as a theranostic, thepHLOGISTIX strategy is to focus on mitochondrial components released from the brain after traumatic impact. We consider these “mitochondrial releasates” and they include mitochondrial DNA (mtDNA), both intact and degraded, as well as proteins transcribed from either mtDNA or nuclear DNA, but that are known to be highly localized to brain mitochondria. Provisional patent applications have been submitted for development of “mitochondrial releasates” for mild TBI and concussion. These tests are all currently in development stage. We anticipate going to clinical trials for the CDx within the next 36 months, while the theranostic is likely to take more time.